Skip to content

effectiveness of chionanthus virginica in gallstone

A Comparitive study of action of Chionanthus Virginica in 200 and 50 Millesmal potency in Gallstones

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2023/10/058738
Enrollment
150
Registered
2023-10-17
Start date
Unknown
Completion date
Unknown
Last updated
2023-11-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: K802- Calculus of gallbladder without cholecystitis

Interventions

Intervention1: Chionanthus 200 Chionanthus 0/3: Chionanthus 200, 3 dose in a week for a month Chionanthus 0/3, daily 1 dose morningfor a month Intervention2: Chionanthus viriginica 200 and 50 MIllesi

Sponsors

Preena Jane J
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: patients with pain in right hypochondrium nausea indigestion fatty stool will bw included

Exclusion criteria

Exclusion criteria: case with complication acute cholicystities Gallblader cancer Blocked duct are not included

Design outcomes

Primary

MeasureTime frame
to find the effectiveness of chionanthus virginica 200 and 50 millesimal potency in the management of gallstone cases by reducing the symptoms and size of stoneTimepoint: 24 WEEKS

Secondary

MeasureTime frame
To experiment and compare the action of Chionanthus virginica 200 & 50 millesimal in treating Gallstones. 2. To find out a comparative effect of Chionanthus 200 and 50 millesimal in male and female patients with Gallstones. 3.To find the effect of Chionanthus 200 and 50 millesimal in obese patients with gallstones, 4.to find the effect of Chionanthus 200 and 50 millesimal in patients who lead a sedentary lifestyle diagnosed with gallstones.Timepoint: 24 WEEKS

Countries

India

Contacts

Public ContactDrNisha Paul

Vinayaka Mission HomoeopathIC Medical College and Hospital

nisha.gopal2012@gmail.com9995680275

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026